This post was originally published on this site A combination of oral Lynparza (olaparib) and weekly chemotherapy can be safely given to heavily treated ovarian cancer patients and shows signs of efficacy, particularly among those with BRCA mutations, a Phase 1/2 trial shows. The findings suggest that weekly chemotherapy might be more suitable for these patients…
This post was originally published on this site Losartan, a medicine used for treating high blood pressure, might improve ovarian cancer treatment by making it easier for chemotherapy drugs to get to tumor cells, a study found. Patients with advanced ovarian cancer receiving losartan or other similar angiotensin signaling inhibitors lived a median 30 months longer on standard…
This post was originally published on this site The Multiple Myeloma Research Foundation (MMRF) is reworking its executive team, with a focus on improving multiple myeloma patient outcomes and advancing its precision medicine program. Steve Labkoff, MD, becomes the organization’s first chief data officer, while Michael Andreini is the new chief operating officer. Meanwhile, Daniel Auclair,…
This post was originally published on this site The development and commercialization of TNB-383B — an anti-BCMA antibody for the potential treatment of multiple myeloma — is being advanced as part of a new collaboration between AbbVie, Teneobio, and its affiliate TeneoOne. Under terms of the agreement, TeneoOne will continue to develop TNB-383B through Phase 1 clinical…
This post was originally published on this site More than half of all deaths related to asbestos exposure is caused by malignant mesothelioma, a new study has shown. The study, “Risk Factors of Mortality from All Asbestos-Related Diseases: A Competing Risk Analysis,” was published in the journal Canadian Respiratory Journal. Asbestos is known to be responsible for several…
This post was originally published on this site A case study diagnosing sarcoidosis upon autopsy in a patient with acute respiratory distress syndrome (ARDS) of unknown cause highlights the importance of physicians taking into account this uncommon disease association for quicker diagnosis and treatment. The study, “Sarcoidosis Presenting as Acute Respiratory Distress Syndrome,” was published in…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) is updating its 2015 draft guidelines for drug discovery in rare diseases, with new guidance on natural history — how disorders such as spinal muscle atrophy (SMA) run their course if untreated — the choice of “efficacy endpoints” in clinical…
This post was originally published on this site Deaths attributed to sarcoidosis as the primary underlying cause increased between 1999 and 2016 in the United States, according to a recent observational study. The study, “Sarcoidosis deaths in the United States: 1999–2016,” published in the journal Respiratory Medicine, compared death rates among different regions, races, genders,…
This post was originally published on this site Two cardiologists in the Netherlands are using an artificial intelligence (AI) tool called the VMS Heart Analysis System, developed by Ventripoint Diagnostics, for the early diagnosis of pulmonary hypertension in sarcoidosis patients. With this tool, Marco Post, MD, PhD, and Marloes Huitema, MD, at the St. Antonius…
This post was originally published on this site A research team at Yale School of Medicine successfully treated a person with disfiguring sarcoidosis with Xeljanz (tofacitinib) — an existing approved treatment against rheumatoid arthritis — resulting in a near-complete disappearance of skin lesions. The findings were published in the New England Journal of Medicine in…
